NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered peptides from Cellupep? Mail in a sample (US only) and let us test it.

Test my supply
+8 more ↓
63%
Finnrick rating
#398 of 500 ranked vendors
28 of 43 classifiable tests passed
methodology · Purity focus
Finnrick analysis

Cellupep's purity-focus record is strongest in GHK-Cu, Tirzepatide, and Retatrutide, though Retatrutide shows volatility rather than a clean trend. Weakness clusters in BPC-157, TB-500, and Tesamorelin, with BPC-157 purity misses, TB-500 purity and fill swings, current testing, and uneven batch identifiers.

methodology →
vendor intelligence report
Vendor Intelligence Report: Cellupep

Corporate and domain records point to a recent, privacy-protected operation behind Cellupep’s manufacturer-style claims. The full report follows the COA gallery, UK/HK contact layer, European storefront, and mixed fulfillment trail without relying on vendor screenshots.

26 pages6 risk factors assessed2 Jul 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.07
84%
5
2
Tirzepatide
$0.48
79%
7
3
Retatrutide
$1.00
77%
18
4
Tesamorelin
$2.00
49%
4
5
BPC-157
$0.75
42%
6
6
TB-500
$1.26
41%
4
7
Glutathione
$0.01
-
0
8
HGH
$1.33
-
0
9
Ipamorelin
$1.10
-
0
10
KPV
$0.50
-
0
11
MOTS-c
$0.68
-
0
12
NAD+
$0.01
-
0
13
PT-141
$0.75
-
0
15
SS-31
$0.84
-
0
16
Wolverine
$0.85
-
0
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%17 Nov 2025: 52%25 Nov 2025: 46%13 Dec 2025: 46%17 Dec 2025: 47%7 Jan 2026: 47%7 Jan 2026: 47%26 Jan 2026: 48%26 Jan 2026: 47%18 Feb 2026: 54%18 Feb 2026: 57%18 Feb 2026: 59%18 Feb 2026: 60%18 Feb 2026: 60%18 Feb 2026: 60%20 Feb 2026: 60%20 Feb 2026: 61%20 Feb 2026: 61%22 Feb 2026: 61%22 Feb 2026: 61%17 Mar 2026: 62%17 Mar 2026: 62%18 Mar 2026: 62%19 Mar 2026: 62%19 Mar 2026: 62%22 Mar 2026: 62%25 Mar 2026: 62%28 Apr 2026: 62%28 Apr 2026: 62%11 May 2026: 62%11 May 2026: 62%13 Jul 2026: 62%13 Jul 2026: 62%20 Jul 2026: 62%2 Aug 2026: 64%3 Aug 2026: 65%3 Aug 2026: 65%9 Aug 2026: 64%9 Aug 2026: 63%14 Oct 2026: 64%27 Oct 2026: 63%17 Nov 2026: current 63%52%62%63%Nov 25Nov 26
Peptide testing

Ordered peptides from Cellupep? Mail in a sample (US only) and let us test it.

Test my supply
Cellupep test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
27 Oct 2026
Fail
Retatrutide
lab nameView COA
14 Oct 2026
Pass
Retatrutide
lab nameView COA
9 Aug 2026
Fail
Tirzepatide
lab nameView COA
9 Aug 2026
Fail
Retatrutide
lab nameView COA
3 Aug 2026
Pass
Tirzepatide
lab nameView COA
3 Aug 2026
Pass
Retatrutide
lab nameView COA
2 Aug 2026
Pass
Tesamorelin
lab nameView COA
20 Jul 2026
Pass
Tirzepatide
lab nameView COA
20 Jul 2026
Incomplete
Tirzepatide
lab nameView COA
13 Jul 2026
Fail
BPC-157
lab nameView COA
1-10 of 44

About Cellupep test results from Finnrick

Cellupep is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 6 peptides and 44 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Cellupep peptides in this dataset are BPC-157 (6 tests), GHK-Cu (5 tests) and Retatrutide (18 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 44 recent tests.

Corrections
No corrections.
Peptide testing

Ordered peptides from Cellupep? Mail in a sample (US only) and let us test it.

Test my supply